Mark Rothera
2014 - PTC Therapeutics
In 2014, Mark Rothera earned a total compensation of $2M as Chief Commercial Officer at PTC Therapeutics, a 2% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $297,360 |
|---|---|
| Option Awards | $1,318,493 |
| Salary | $413,000 |
| Other | $5,148 |
| Total | $2,034,000 |
Rothera received $1.3M in option awards, accounting for 65% of the total pay in 2014.
Rothera also received $297.4K in non-equity incentive plan, $413K in salary and $5.1K in other compensation.
Rankings
In 2014, Mark Rothera's compensation ranked 4,448th out of 13,032 executives tracked by ExecPay. In other words, Rothera earned more than 65.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,448 out of 13,032 | 66th |
Division Manufacturing | 1,586 out of 4,967 | 68th |
Major group Chemicals And Allied Products | 524 out of 1,690 | 69th |
Industry group Drugs | 403 out of 1,369 | 71st |
Industry Pharmaceutical Preparations | 320 out of 1,042 | 69th |
Source: SEC filing on April 27, 2017.
Rothera's colleagues
We found three more compensation records of executives who worked with Mark Rothera at PTC Therapeutics in 2014.